International licensing success for Iksuda Therapeutics
The agremment sees Iksuda Therapeutics working with South Korean firm LegoChem Biosciences, Inc for the development and commercialization of LCB73, a CD19-targeted Antibody-Drug Conjugate (ADC) candidate for hematological tumors.
LCB73 has been created in a partnership between LegoChem Biosciences and Swiss-based Light Chain Bioscience’s (Novimmune SA). This was possible by combining LCB’s cancer-selectively activated next-generation linker and toxin platform with Light Chain Bioscience’s proprietary antibody targeting CD19.
Preclinical data of LCB73 along with the clinical outcome of other CD19-targeted therapies suggest that the ADC may be an effective treatment option for various Bcell hematological cancers including diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma.
Dr. Yong-Zu Kim, CEO & President of LCB said: "“We are very pleased to expand our partnership with Iksuda to advance the development of LCB73, in addition to the recent license agreement which enables the application of our ADC platform to Iksuda’s pipeline of Next Generation ADCs.
“This particular ADC program will set a significant milestone as it is our first lead ADC candidate utilizing our next-generation prodrug payload, whose commercial and clinical potential will be explored through this collaboration.”
Dr David Simpson, CEO of Iksuda therapeutics said: “We have been very impressed with preclinical data using LCB73 which have demonstrated significant single-agent anti-cancer activity in B cell malignancies and a competitive toxicity profile.
“We look forward to advancing this candidate into the clinic in the most efficient manner, utilizing our extensive UK and US based ADC expertise to drive preclinical and clinical development activities.”